$3080 | SAVE $420 | Single User
$6160 | SAVE $840 | Site License
$9240 | SAVE $1,260 | Enterprise License

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 30 Nov 2016 | 39833 | In Stock
Related Topics: Protein

Introduction

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)

- The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    List of Tables 5

    List of Figures 5

    Introduction 6

    Global Markets Direct Report Coverage 6

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Overview 7

    Therapeutics Development 8

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Products under Development by Stage of Development 8

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Products under Development by Therapy Area 9

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Products under Development by Indication 10

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Products Glance 12

    Late Stage Products 12

    Early Stage Products 13

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Products under Development by Companies 14

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Products under Development by Universities/Institutes 17

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Assessment 19

    Assessment by Monotherapy/Combination Products 19

    Assessment by Mechanism of Action 20

    Assessment by Route of Administration 21

    Assessment by Molecule Type 23

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Companies Involved in Therapeutics Development 25

    Advenchen Laboratories LLC 25

    Athenex Inc 26

    Basilea Pharmaceutica Ltd 27

    Pfizer Inc 28

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Drug Profiles 29

    apatinib - Drug Profile 29

    Product Description 29

    Mechanism Of Action 29

    R&D Progress 29

    bosutinib - Drug Profile 32

    Product Description 32

    Mechanism Of Action 32

    R&D Progress 32

    CCT-196969 - Drug Profile 36

    Product Description 36

    Mechanism Of Action 36

    R&D Progress 36

    CCT-241161 - Drug Profile 37

    Product Description 37

    Mechanism Of Action 37

    R&D Progress 37

    eCF-506 - Drug Profile 38

    Product Description 38

    Mechanism Of Action 38

    R&D Progress 38

    KX-01 - Drug Profile 39

    Product Description 39

    Mechanism Of Action 39

    R&D Progress 39

    KX-02 - Drug Profile 41

    Product Description 41

    Mechanism Of Action 41

    R&D Progress 41

    PP-1 - Drug Profile 43

    Product Description 43

    Mechanism Of Action 43

    R&D Progress 43

    Small Molecule to Inhibit c-Src Tyrosine Kinase for Oncology - Drug Profile 44

    Product Description 44

    Mechanism Of Action 44

    R&D Progress 44

    Small Molecules to Inhibit Src Kinase for Oncology - Drug Profile 45

    Product Description 45

    Mechanism Of Action 45

    R&D Progress 45

    Small Molecules to Inhibit Src Tyrosine Kinase for Colon Cancer - Drug Profile 46

    Product Description 46

    Mechanism Of Action 46

    R&D Progress 46

    Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer - Drug Profile 47

    Product Description 47

    Mechanism Of Action 47

    R&D Progress 47

    UM-164 - Drug Profile 48

    Product Description 48

    Mechanism Of Action 48

    R&D Progress 48

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Dormant Projects 49

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Discontinued Products 50

    Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Featured News & Press Releases 51

    Oct 18, 2016: Athenex announces Xiangxue Pharmaceuticals, its KX-02 development partner in China, has achieved a regulatory milestone in that territory 51

    Aug 24, 2016: NICE approves new cancer drug bosutinib for routine NHS use 51

    Jul 26, 2016: LSK BioPharma Announces Successful Outcome from End-of-Phase 2 meeting with FDA 52

    Jul 07, 2016: NICE approves first drug from old Cancer Drugs Fund 52

    Jun 08, 2016: New compound shows potential for triple-negative breast cancer 53

    May 23, 2016: Breast cancer drug discovery offers hope of new treatments 54

    Sep 15, 2015: Avillion Announces Completion of Enrolment in Phase III BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 55

    Feb 18, 2015: Particle Sciences Manufactures Clinical Supplies for Kinex's Glioblastoma Therapeutic 55

    Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study 56

    Dec 24, 2014: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 56

    Dec 09, 2014: Pfizer Demonstrates New Data On BOSULIF at ASH 2014 57

    Aug 11, 2014: Avillion Announces Dosing of First Patients in Phase 3 BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 57

    Jul 24, 2014: Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 58

    Mar 30, 2014: Atlantic Research Group Client Kinex Pharmaceuticals Initiate Phase I Glioblastoma trial 59

    Jan 09, 2014: Avillion Partners with Pfizer to Co-develop BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 59

    Appendix 61

    Methodology 61

    Coverage 61

    Secondary Research 61

    Primary Research 61

    Expert Panel Validation 61

    Contact Us 61

    Disclaimer 62

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

39833 | GMDHC0695TDB

Number of Pages

62

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Review, H2 2018
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Tra...
20 Nov 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Pipeline Review, H2 2016
Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK o...
21 Dec 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H2 2016
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Typ...
30 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Pipeline Review, H2 2016
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DY...
16 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine ...
16 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or ...
16 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Pipeline Review, H2 2016
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Ty...
16 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2016
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or Trk...
16 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016SummaryGlo...
09 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemi...
26 Oct 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...